FDA Greenlights Osteoporosis Drug for Postmenopausal Women
FDA Advisory Committee Votes in Favor of Romosozumab Approval
Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
Romosozumab Has Biggest BMD Benefit in First Year of Treatment
Novel Bone Drug Promising in Postmenopausal Osteoporosis
Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA
Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval
